# Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis

Study · id `cardio:ct-nct03183245` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03183245](<https://clinicaltrials.gov/study/NCT03183245>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03183245

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 242 participants.

## Technical summary

Registry record NCT03183245. Randomized; no masking; primary purpose treatment. Start 2017-09-29 (actual); primary completion 2024-04-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 242 participants (enrolled count; ClinicalTrials.gov record NCT03183245, source copy `cardio:ctgov-nct03183245-2025-11-20`, retrieved 2026-10-26)
- Started: 2017-09-29 (actual) (ClinicalTrials.gov record NCT03183245, source copy `cardio:ctgov-nct03183245-2025-11-20`, retrieved 2026-10-26)
- Primary completion: 2024-04-22 (actual) (ClinicalTrials.gov record NCT03183245, source copy `cardio:ctgov-nct03183245-2025-11-20`, retrieved 2026-10-26)
- Completion: 2025-06-19 (actual) (ClinicalTrials.gov record NCT03183245, source copy `cardio:ctgov-nct03183245-2025-11-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03183245, source copy `cardio:ctgov-nct03183245-2025-11-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03183245-2025-11-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
- Condition: Renal Failure
- Condition: End Stage Renal Disease
- Condition: Hemodialysis
- Condition: Vascular Access
- Intervention (Biological): Human Acellular Vessel (HAV)
- Intervention (Procedure): Arteriovenous fistula (AVF)
- Intervention (Other): Hemodialysis
- Lead sponsor: Humacyte, Inc.
- Lead sponsor class: INDUSTRY
- Collaborator: CTI Clinical Trial and Consulting Services
- Collaborator class: OTHER
- Collaborator: California Institute for Regenerative Medicine (CIRM)
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Humacyte, Inc. (`cardio:org-humacyte-inc`)
- Registry lists this organization as a collaborator: California Institute for Regenerative Medicine (CIRM) (`cardio:org-california-institute-for-regenerative-medicine-cirm`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Bioengineered acellular tissue engineered vessels versus autogenous fistulae for haemodialysis access: a multicentre, randomised, controlled, phase 3 trial (`cardio:pubmed-42613284`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a87ddf0589faf476c792f0bfce8b1ed7fd50c230bebe5120c90c6f79b06744b0
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
